- Home
- PMEC vs ACET Comparison
PMEC vs ACET Comparison
Compare PMEC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | ACET |
|---|---|---|
| Founded | 1984 | 1947 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 93.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMEC | ACET |
|---|---|---|
| Price | $1.08 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 193.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,349,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $0.54 | $0.45 |
| 52 Week High | $2.44 | $1.12 |
Technical Indicators
Market Signals| Indicator | PMEC | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 33.71 |
| Support Level | $0.97 | $0.53 |
| Resistance Level | $1.10 | $0.57 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 58.54 | 5.35 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.